RxDoctor Payments DataLook up a doctor →

Francis Palermo, MD

Cardiovascular Disease · Newark, DENPI 1467553982

Payments from drug & device makers

$16,545in general payments, 2019–2025

Across 746 payments — averaging $22.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Novartis$2K
  • Sanofi-aventis U.S. LLC$2K
  • Pfizer$1K
  • Johnson & Johnson$1K
  • Boehringer Ingelheim$972
  • plus $6K from 22 others

What the payments were for

  • Consulting fees$1,1147%
  • Food & beverage$15,12691%
  • Education$3052%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,545 in reported general payments places this provider in the 75th percentile of 104 cardiovascular disease providers in Delaware.

See all cardiovascular disease providers in Delaware

Medicare billing

Part B allowed, 2024
$564,051
Medicare patients
699
Services billed
6,060

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban87$110,287
XareltoRivaroxaban70$84,555
EntrestoSacubitril/Valsartan50$62,251
JardianceEmpagliflozin25$32,501
OzempicSemaglutide20$18,577
Repatha SureclickEvolocumab17$16,579
Rosuvastatin Calcium156$5,288
Carvedilol365$4,948
Flecainide Acetate57$3,140
Atorvastatin Calcium139$2,328
Amiodarone Hcl110$1,965
Ezetimibe33$1,574
Hydralazine Hcl67$1,544
Lisinopril122$1,538
Valsartan30$1,231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,135$110,28787 claims
Johnson & JohnsonXarelto$1,001$84,55570 claims
NovartisEntresto$1,612$62,25150 claims
Boehringer IngelheimJardiance$972$32,50125 claims
Novo NordiskOzempic$468$18,57720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 104 cardiovascular disease providers in Delaware.

Other cardiovascular disease in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →